A few weeks ago, we wrote Hemispherx Biopharma’s (HEB – $2.73) shares were on a rollercoaster and it seems the ride is getting wilder and wilder.
Obviously, there’s a tremendous amount of speculation about the FDA’s decision to approve Ampligen for Chronic Fatigue Syndrome (CFS). Based on all the public information out there, you have to form an opinion, and we believe Ampligen has a fair chance to be approved.
Also feeding the speculation, was Hemispherx’ press release on Thursday about the publication of an article in Therapeutics and Clinical Risk Management. The article summarizes ongoing research in which researchers conclude that Ampligen is the “most promising adjuvant candidate for mucosal vaccines.” The article further stated that Ampligen was also “extremely important” in these studies, in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone.
Simply terrific news we believe, and another indication that Ampligen can be used to combat various diseases.
We also had a couple of publications by “journalist” Adam Feuerstein from Thestreet.com. We emphasize journalist, because according to Wikipedia the definition of a journalist is: “A person who practices journalism, the gathering and dissemination of information about current events, trends, issues, and people while striving for viewpoints that aren’t biased.”
We guess Mr. Feuerstein forgot about that last sentence in his latest articles. In his first piece he wrote: “In fact, Hemispherx reminds me so much of Biopure (BPUR), the old human blood substitute company. That story ended badly, and so will Hemispherx.” And in his second one he wrote : “… you get the picture of a company desperately trying to pump up its stock price before the FDA rejects Ampligen.”
That isn’t objective an unbiased, in fact Wikipedia also has a definition for this kind or reporting: gutter journalism.
Undoubtedly, Hemispherx could take legal action against Thestreet.com for spreading misleading information, but I would prefer them to concentrate their time and energy on moving the business forward.
When we recommended the Company in January, its shares were trading at 36 cents. If you bought back then, you have a 750% return. If you are afraid to loose some or all of those gains, we advice you to sell on Monday. After all, it doesn’t happen every day you can sell at such a nice profit.
However, if your stomach can stand the rollercoaster ride (like ours can), hang in there and wait for the FDA’s decision.
Photo credit marada